Regeneron Pharmaceuticals Q4 Earnings: Revenue Falls As COVID-19-Related Sales Dwindle

  • Regeneron Pharmaceuticals Inc REGN earned $12.56 per share for Q4 FY22, down 46% Y/Y, beating the $10.03 Street estimate. 
  • Revenues decreased 31% Y/Y to $3.41 billion; excluding REGEN-COV and Ronapreve, revenues increased 14%, slightly ahead of the analyst consensus of $3.13 billion.
  • The company recorded no sales in the quarter for its COVID-19 antibody drug due to the FDA's decision to limit its use in January last year in all states because of a lack of effectiveness against the omicron variant.
  • Eylea U.S. net sales decreased by 3% to $1.5 billion due to a short-term shift to off-label use of compounded bevacizumab and a temporary closing of a not-for-profit fund providing patient co-pay assistance.
  • Volumes of U.S. EYLEA in Q4 increased compared to a year ago.
  • Related: UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent.
  • The operating margin compressed from 53.3% to 33.6%.
  • The company announced a new $3-billion share repurchase program authorized in January 2023.
  • The company's net income fell to $1.2 billion, or $10.50 per share, in the quarter that ended Dec. 31, from $2.23 billion, or $19.69 per share, a year earlier.
  • Price Action: REGN shares closed at $751.20 on Thursday.



  •  

 

 

 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsEarnings BeatsLarge CapNewsHealth CareTop StoriesGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!